T28zT2 T cells also demonstrated effective suppression of tumor growth in two HCC patient-derived xenograft (PDX) models (Figures S2A and S2B), and both T28zT2 T cells and anti-MSLN CAR T cells (M28zT2 T cells) effectively inhibited tumor progression in HeLa xenografts (Figures S2C and S2D). This evidence concerns the gene MSLN and hepatocellular carcinoma.